New drug policy indicators in Southeast Asia: Implications from research in Thailand

Kanna Hayashi, PhD
Assistant Professor
Department of Medicine, University of British Columbia
Research Scientist
British Columbia Centre for Excellence in HIV/AIDS
Key Policy Indicators to Consider

• Coverage and accessibility of evidence-based interventions identified by WHO/UNODC/UNAIDS as part of the comprehensive package for HIV prevention, treatment and care for people who inject drugs*

• Coverage and accessibility of evidence-based treatment for substance use disorders

*Needle and syringe programs; opioid agonist therapies; HIV testing and counseling; prevention and treatment of sexually transmitted infections; condom programmes for PWID and their sexual partners; targeted information, education and communication for PWID and their sexual partners; prevention, vaccination, diagnosis and treatment for viral hepatitis; prevention, diagnosis and treatment of tuberculosis
PWID Account for 30% of New HIV Cases outside sub-Saharan Africa

HIV prevalence among people who inject drugs compared to the general population in countries reporting >30 000 people who inject drugs, 2009–2013

HIV Epidemic among Thai PWID


- Injection drug users
- Direct female commercial sex workers
- Indirect female commercial sex workers
- Male clients at STI clinics
- Blood donors
- Pregnant women at antenatal care clinics

Thai Ministry of Public Health
Provision of Harm Reduction Services

• Primarily through international funding (e.g., GF)

PWID who had difficulty accessing sterile syringes were more likely to access the drop-in center.
Ensuring Service Coverage is Urgently Required.

- GF Funding was cut in half in 2015.
  - Coverage down from 19 → 12 provinces

- Domestic funding plans post 2017 remain unknown.
Adhering to evidence-based standards of drug addiction treatment is also important.
Opioid Agonist Maintenance Therapy: The Gold Standard

- Methadone maintenance therapy:
  - Opioid use
  - Criminal activities
  - HIV risk
  - Overdose
  - Mortality
- Recommended dose: 60-120mg/day
- In 2008, added to the universal healthcare coverage in Thailand.
Quality Issues of MMT

• In 2011, a median dosage of methadone was **30mg** among 158 MMT patients in Bangkok.
  - 16% used street methadone.
  - 19% reported syringe sharing.

*Hayashi et al. Work in progress*
Quality Issues of MMT

• In 2011, a median dosage of methadone was 30mg among 158 MMT patients in Bangkok.
  o 16% used street methadone.
  o 19% reported syringe sharing.

• Methadone Providers’ Negative Attitudes Toward Methadone:
  “I told him [i.e., a doctor who prescribed methadone] that I wanted to take the treatment. Then, he advised me to go cold turkey and not to believe Western doctors. He said, “This drug is from the West. Westerners are tricking us.” He was quite anti-Western medicine.”
  (Respondent #7, male, age 36)

Hayashi et al. Work in progress
In Thailand, an estimated 60% of those accessing ‘drug treatment’ are placed in CDDCs in 2011.

ONCB, 2011
Violence & Neglect in CDDCs

“They did not provide any therapy...they just brought us into an environment that was like torture. As soon as they arrived, they just shoved us and kicked us behind bars, and then left us there without doing anything...I suffered withdrawal symptoms...I couldn’t sleep, couldn’t eat and threw up whatever I ate.”
CDDCs Not Effective in Treating SUDs

Compulsory drug detention and injection drug use cessation and relapse in Bangkok, Thailand

NADIA FAIRBAIRN¹, KANNA HAYASHI¹,², LIANPING TI¹,³, KARYN KAPLAN⁴, PAISAN SUWANNAWONG⁴, EVAN WOOD¹,⁵ & THOMAS KERR¹,⁵

CDDC exposure was significantly associated with short-term (3-12 months) but not long-term (>12 months) cessation of injecting.
Ensuring accessibility is also important
R: They said, “Help the nation with some work! What charge do you want?”

I: Did they find any drugs on you when they said that?

R: No! But I knew what charge I should go for. So, I picked the one with the minimum sentence.

I: Did they let you pick a light charge?

R: Mostly they do, because that way, they can arrest you again after you’ve been released.

(Respondent #26, male, age 36)
“When they [the police] were campaigning against drug use, we couldn’t even get into the methadone clinic. We had to wait. And we couldn’t hang around there and let them see us either. They would often wait for us along the routes we use. I’ve run into trouble with them two or three times.”

(Respondent #5, male, age 50)
57% of 190 MMT patients reported noticing police presence near methadone clinics, and were more likely to report:

- Avoiding healthcare
- High intensity midazolam injection

Of these, 19% discontinued methadone due to:

- Incarceration (33%)
- Difficulty accessing clinics (19%)
Key Policy Indicators to Consider

• Coverage and accessibility of evidence-based interventions identified by WHO/UNODC/UNAIDS as part of the comprehensive package for HIV prevention, treatment and care for people who inject drugs*

• Coverage and accessibility of evidence-based treatment for substance use disorders

*Needle and syringe programs; opioid agonist therapies; HIV testing and counseling; prevention and treatment of sexually transmitted infections; condom programmes for PWID and their sexual partners; targeted information, education and communication for PWID and their sexual partners; prevention, vaccination, diagnosis and treatment for viral hepatitis; prevention, diagnosis and treatment of tuberculosis
Acknowledgment

• Participants in the Mitsampan Community Research Project

• Staff & volunteers at TTAG, Mitsampan Harm Reduction Center & O-Zone House: Jirasak Sripramong, Kamon Uppakaew, Amnat Chamchern, Vipawan Suwannawong, Wiwat Chotichatmala, Prapatsara Kaewkoon, and Pascal Tanguay

• Chulalongkorn University: Dr. Niyada Kiatying-Angsulee

• BC CfE staff: Tricia Collingham, Cameron Dilworth, Deborah Graham, Caitlin Johnston, Daniel Miles Kane, Calvin Lai, Cristy Power, and Peter Vann

• Research assistants: Arphatsaporn Chaimongkon, Sattara Hattirat, and Puripakorn Pakdirat

• Funders: Michael Smith Foundation for Health Research, Open Society Foundations, Canadian Institutes of Health Research (supports KH).